Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the initiation ...

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...

Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy ("RMT") in inflammatory and fibrotic ...

Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated ...

Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December ...

The newly announced restructure includes several company leaders hitting the exit and the discontinuation of the biotech’s ...

Richard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both immune oncology and inflammatory diseases. In healthy tissues ...

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of ...

Researchers at the University of Kentucky are exploring new ways to use nanoparticles in combination with other materials as ...

封底插图： 在肿瘤内部恶劣的环境中，膀胱癌细胞（喻为 红鱼 ）通过释放趋化因子CCL2来吸引巨噬细胞（喻为黑鱼）。作为响应，巨噬细胞释放细胞因子IL-6，辅助肿瘤细胞的增殖和干性维持，形成了一种促进肿瘤恶性生长的共生关系。这种互作关联揭示了肿瘤微环境中细胞间复杂的相互作用，也凸显了肿瘤进展中的关键调控机制。

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to ...